Spinal Muscular Atrophy

  • Jérémie Vitte
  • Ruben Attali
  • Nasim Warwar
  • Irena Gurt
  • Judith MelkiEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 652)


Spinal muscular atrophies (SMA) are frequent autosomal recessive disorders characterized by degeneration of lower motor neurons. SMA are caused by mutations of the survival of motor neuron gene (SMN1) leading to a reduction of the SMN protein amount. The identification of SMN interacting proteins involved in the formation of the spliceosome and splicing changes in SMN-deficient tissues of mutant mice strongly support the view that SMN is involved in the splicing reaction. However, the molecular pathway linking SMN defect to the SMA phenotype remains unclear. From a better knowledge of the genetic basis of SMA and the defects resulting from the mutations of SMN1 in cellular or animal models, several therapeutics strategies have been selected aiming at targeting SMN2, a partially functional copy of SMN1 gene which remains present in patients, or to prevent neurons from death. Refined characterization of the degenerative process in SMA and the identification of the defective molecular pathway downstream from the SMN defect will provide further exciting insight into this disease in the near future. They should contribute to clarify the pathophysiology of SMA, the function of SMN and should help in designing potential targeted or non-targeted therapeutic molecules.


Spinal muscular atrophy SMN Motor neuron disease Splicing 



Work made in our laboratory was supported by INSERM, the University of Evry, the Association Française contre les Myopathies, Families of SMA (U.S.A) and the Foundation Bettencourt Schueller. We gratefully thank Natacha Roblot, Bénédicte Desforges, Gaelle Millet, Vandana Joshi, and Vilayphone Vongsa for their invaluable assistance.


  1. 1.
    Andreassi C, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10:2841–2849.CrossRefPubMedGoogle Scholar
  2. 2.
    Baron-Delage S, et al. Interferons and IRF-1 induce expression of the survival motor neuron (SMN) genes. Mol Med 2000; 6:957–968.PubMedGoogle Scholar
  3. 3.
    Brichta L, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12:2481–2489.CrossRefPubMedGoogle Scholar
  4. 4.
    Campbell L, et al. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet 1997; 61:40–50.CrossRefPubMedGoogle Scholar
  5. 5.
    Chan YB, et al. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum Mol Genet 2003; 12:1367–1376.CrossRefPubMedGoogle Scholar
  6. 6.
    Chang JG, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA 2001; 98:9808–9813.CrossRefPubMedGoogle Scholar
  7. 7.
    Cifuentes-Diaz C, et al. Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J Cell Biol 2001; 152:1107–1114.CrossRefPubMedGoogle Scholar
  8. 8.
    Cifuentes-Diaz C, et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Hum Mol Genet 2002; 11:1439–1447.CrossRefPubMedGoogle Scholar
  9. 9.
    Cisterni C, et al. Death of motoneurons induced by trophic deprivation or by excitotoxicity is not prevented by overexpression of SMN. Neurobiol Dis 2001; 8:240–251.CrossRefPubMedGoogle Scholar
  10. 10.
    Coovert DD, et al. The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 1997; 6:1205–1214.CrossRefPubMedGoogle Scholar
  11. 11.
    Eggert C, et al. Spinal muscular atrophy: the RNP connection. Trends Mol Med 2006; 12:113–121.CrossRefPubMedGoogle Scholar
  12. 12.
    Fischer U, et al. The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 1997; 90:1023–1029.CrossRefPubMedGoogle Scholar
  13. 13.
    Frugier T, et al. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet 2000; 9:849–858.CrossRefPubMedGoogle Scholar
  14. 14.
    Frugier T, et al. The molecular bases of spinal muscular atrophy. Curr Opin Genet Dev 2002; 12:294–298.CrossRefPubMedGoogle Scholar
  15. 15.
    Gabanella F, et al. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE. 2007 2:e921.Google Scholar
  16. 16.
    Grzeschik SM, et al. Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005; 58:194–202.CrossRefPubMedGoogle Scholar
  17. 17.
    Haddad H, et al. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle and Nerve 2003; 28:432–437.CrossRefPubMedGoogle Scholar
  18. 18.
    Hsieh-Li HM, et al. A mouse model for spinal muscular atrophy. Nat Genet 2000; 24:66–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Jarecki J, et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005; 14:2003–2018.CrossRefPubMedGoogle Scholar
  20. 20.
    Kariya S, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet. 2008 May 20 [Epub ahead of print].Google Scholar
  21. 21.
    Kerr DA, et al. Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci USA 2000; 97:13312–13317.CrossRefPubMedGoogle Scholar
  22. 22.
    Kernochan LE, et al. The role of histone acetylation in SMN gene expression. Hum Mol Genet 2005; 14:1171–1182.CrossRefPubMedGoogle Scholar
  23. 23.
    Kolb SJ, et al. A novel cell immunoassay to measure survival of motor neurons protein in blood cells. BMC Neurol 2006; 6:6.CrossRefPubMedGoogle Scholar
  24. 24.
    Lefebvre S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80:155–165.CrossRefPubMedGoogle Scholar
  25. 25.
    Lefebvre S, et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16:265–269.CrossRefPubMedGoogle Scholar
  26. 26.
    Le TT, et al. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 2005; 14:845–857.CrossRefPubMedGoogle Scholar
  27. 27.
    Lesbordes JC, et al. Therapeutic benefits of cardiotrophin-1 gene transfer in a mouse model of spinal muscular atrophy. Hum Mol Genet 2003; 12:1233–1239.CrossRefPubMedGoogle Scholar
  28. 28.
    Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. Embo J 1996; 15:3555–3565.PubMedGoogle Scholar
  29. 29.
    Liu Q, et al. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997; 90:1013–1021.CrossRefPubMedGoogle Scholar
  30. 30.
    Lorson CL, et al. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998; 19:63–66.CrossRefPubMedGoogle Scholar
  31. 31.
    Lorson CL, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 1999; 96:6307–6311.CrossRefPubMedGoogle Scholar
  32. 32.
    Lunn MR, et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 2004; 11:1489–1493.CrossRefPubMedGoogle Scholar
  33. 33.
    McWhorter ML, et al. Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J Cell Biol 2003; 162:919–931.CrossRefPubMedGoogle Scholar
  34. 34.
    Miguel-Aliaga I, et al. The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum Mol Genet 1999; 8:2133–2143.CrossRefPubMedGoogle Scholar
  35. 35.
    Monani UR, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000; 9:333–339.CrossRefPubMedGoogle Scholar
  36. 36.
    Munsat TL. Workshop report: International SMA Collaboration. Neuromuscul Disord 1991; 1:81.Google Scholar
  37. 37.
    Nicole S, et al. Intact satellite cells lead to remarkable protection against Smn gene defect in differentiated skeletal muscle. J Cell Biol 2003; 161:571–582.CrossRefPubMedGoogle Scholar
  38. 38.
    Paushkin S, et al. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol 2002; 14:305–312.CrossRefPubMedGoogle Scholar
  39. 39.
    Pellizzoni L, et al. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998; 95:615–624.CrossRefPubMedGoogle Scholar
  40. 40.
    Rossoll W, et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003; 163:801–812.CrossRefPubMedGoogle Scholar
  41. 41.
    Schrank B, et al. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA 1997; 94:9920–9925.CrossRefPubMedGoogle Scholar
  42. 42.
    Sumner CJ, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54:647–654.CrossRefPubMedGoogle Scholar
  43. 43.
    Sumner CJ, et al. SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 2006; 66:1067–1073.CrossRefPubMedGoogle Scholar
  44. 44.
    Talbot K, et al. Missense mutation clustering in the survival motor neuron gene: a role for a conserved tyrosine and glycine rich region of the protein in RNA metabolism? Hum Mol Genet 1997; 6:497–500.CrossRefPubMedGoogle Scholar
  45. 45.
    Vitte JM, et al. Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. Am J Pathol 2004; 165:1731–1741.PubMedGoogle Scholar
  46. 46.
    Vitte J, et al. Refined characterization of the expression and stability of the SMN gene products. Am J Pathol 2007; 171:1269–1280.CrossRefPubMedGoogle Scholar
  47. 47.
    Vyas S, et al. Involvement of survival motor neuron (SMN) protein in cell death. Hum Mol Genet 2002; 11:2751–2764.CrossRefPubMedGoogle Scholar
  48. 48.
    Wan L, et al. The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. Mol Cell Biol 2005; 25:5543–5551.CrossRefPubMedGoogle Scholar
  49. 49.
    Winkler C, et al. Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev 2005; 19:2320–2330.CrossRefPubMedGoogle Scholar
  50. 50.
    Wolstencroft EC, et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum Mol Genet 2005; 14:1199–1210.CrossRefPubMedGoogle Scholar
  51. 51.
    Zhang HL, et al. Active transport of the survival motor neuron protein and the role of exon-7 in cytoplasmic localization. J Neurosci 2003; 23:6627–6637.PubMedGoogle Scholar
  52. 52.
    Zhang Z, et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell. 2008 133:585–600.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Jérémie Vitte
    • 1
  • Ruben Attali
    • 1
  • Nasim Warwar
    • 1
  • Irena Gurt
    • 1
  • Judith Melki
    • 1
    Email author
  1. 1.Department of Human GeneticsHadassah University HospitalJerusalemIsrael

Personalised recommendations